ARS Pharmaceuticals (SPRY) Competitors $10.11 -0.86 (-7.84%) Closing price 04:00 PM EasternExtended Trading$10.50 +0.39 (+3.86%) As of 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SPRY vs. AKRO, KYMR, MENS, CRNX, NAMS, VKTX, LNTH, MIRM, ZLAB, and ADMAShould you be buying ARS Pharmaceuticals stock or one of its competitors? The main competitors of ARS Pharmaceuticals include Akero Therapeutics (AKRO), Kymera Therapeutics (KYMR), Jyong Biotech (MENS), Crinetics Pharmaceuticals (CRNX), NewAmsterdam Pharma (NAMS), Viking Therapeutics (VKTX), Lantheus (LNTH), Mirum Pharmaceuticals (MIRM), Zai Lab (ZLAB), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. ARS Pharmaceuticals vs. Its Competitors Akero Therapeutics Kymera Therapeutics Jyong Biotech Crinetics Pharmaceuticals NewAmsterdam Pharma Viking Therapeutics Lantheus Mirum Pharmaceuticals Zai Lab ADMA Biologics ARS Pharmaceuticals (NASDAQ:SPRY) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability. Which has preferable valuation & earnings, SPRY or AKRO? ARS Pharmaceuticals has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioARS Pharmaceuticals$89.15M11.21$8M-$0.49-20.63Akero TherapeuticsN/AN/A-$252.06M-$2.00-26.83 Does the media favor SPRY or AKRO? In the previous week, Akero Therapeutics had 25 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 28 mentions for Akero Therapeutics and 3 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.98 beat Akero Therapeutics' score of 0.22 indicating that ARS Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akero Therapeutics 8 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, SPRY or AKRO? ARS Pharmaceuticals has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.29, meaning that its share price is 129% less volatile than the S&P 500. Do analysts recommend SPRY or AKRO? ARS Pharmaceuticals presently has a consensus price target of $33.80, indicating a potential upside of 234.32%. Akero Therapeutics has a consensus price target of $73.38, indicating a potential upside of 36.74%. Given ARS Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe ARS Pharmaceuticals is more favorable than Akero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ARS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86Akero Therapeutics 1 Sell rating(s) 7 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.31 Is SPRY or AKRO more profitable? Akero Therapeutics has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -42.74%. Akero Therapeutics' return on equity of -15.84% beat ARS Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ARS Pharmaceuticals-42.74% -21.85% -15.88% Akero Therapeutics N/A -15.84%-14.59% Do insiders & institutionals believe in SPRY or AKRO? 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 33.5% of ARS Pharmaceuticals shares are owned by insiders. Comparatively, 7.1% of Akero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryARS Pharmaceuticals beats Akero Therapeutics on 11 of the 15 factors compared between the two stocks. Get ARS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SPRY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRY vs. The Competition Export to ExcelMetricARS PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$999.17M$3.02B$6.13B$10.46BDividend YieldN/A57.77%5.73%4.78%P/E Ratio-20.6322.9485.0627.23Price / Sales11.21612.73573.27177.38Price / Cash1,258.81172.6337.3961.86Price / Book3.835.4112.386.64Net Income$8M$33.06M$3.32B$276.79M7 Day Performance-12.69%-2.18%-0.27%-1.54%1 Month Performance7.44%11.60%9.52%5.44%1 Year Performance-38.80%-3.20%71.62%36.30% ARS Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRYARS Pharmaceuticals2.9784 of 5 stars$10.11-7.8%$33.80+234.3%-28.0%$999.17M$89.15M-20.6390AKROAkero Therapeutics3.6473 of 5 stars$53.66-0.4%$73.38+36.7%+79.1%$4.29BN/A-26.8330Insider TradeHigh Trading VolumeKYMRKymera Therapeutics0.801 of 5 stars$59.89+4.7%$61.26+2.3%+40.4%$4.28B$44.71M-17.26170Insider TradeMENSJyong BiotechN/A$55.70+0.8%N/AN/A$4.23BN/A0.0031CRNXCrinetics Pharmaceuticals4.1841 of 5 stars$44.43-1.1%$74.45+67.6%-23.4%$4.18B$1.39M-10.81210NAMSNewAmsterdam Pharma1.782 of 5 stars$37.15+0.3%$42.00+13.1%+112.9%$4.18B$45.56M-22.934News CoverageHigh Trading VolumeVKTXViking Therapeutics3.9443 of 5 stars$33.91+1.0%$86.42+154.8%-46.3%$3.81BN/A-22.1620Upcoming EarningsLNTHLantheus4.5458 of 5 stars$54.59+2.0%$74.50+36.5%-49.5%$3.71B$1.53B14.52700Trending NewsAnalyst RevisionMIRMMirum Pharmaceuticals3.2175 of 5 stars$72.17-0.7%$76.50+6.0%+91.9%$3.63B$429.16M-59.64140Positive NewsAnalyst ForecastAnalyst RevisionZLABZai Lab2.7445 of 5 stars$31.23+3.3%$56.35+80.4%+18.6%$3.49B$398.99M-15.311,869News CoveragePositive NewsADMAADMA Biologics3.5878 of 5 stars$14.55+0.1%$27.67+90.1%-9.0%$3.47B$426.45M16.92530News Coverage Related Companies and Tools Related Companies AKRO Competitors KYMR Competitors MENS Competitors CRNX Competitors NAMS Competitors VKTX Competitors LNTH Competitors MIRM Competitors ZLAB Competitors ADMA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRY) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredIs *BSEM* Oversold??BioStem Technologies Inc. (OTC: BSEM) is emerging as one of the most exciting MedTech stories of 2025. The com...Huge Alerts | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredThe Final DisplacementA new documentary called The Final Displacement is stirring major controversy — and for good reason. It expose...Porter & Company | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
